[Anti-angina activity of potassium-channel activators].
Recently, a new class of drugs has been developed with unique properties with regard to cardiovascular pharmacology: K(+)-channel openers. The increased K+ efflux from smooth muscle cells induced by these drugs is accompanied by a reduced intracellular availability of free Ca++, which in turn induces vascular relaxation. This property is currently being exploited to achieve peripheral and coronary artery dilatation in patients with ischemic heart disease. Cromakalim, pinacidil, and nicorandil, are the most extensively investigated agents in this class. Nicorandil, in addition to its K(+)-channel opener property, also shows a nitrate-like activity on guanylate cyclase of vascular smooth muscle cells. Clinical trials demonstrate that chronic administration of nicorandil can significantly increase exercise tolerance in patients with coronary artery disease. In experimental studies, this drug has also shown protective effects against myocardial injury induced by ischemia and reperfusion, by mechanisms partly independent of its vasodilating properties. These results suggest that K(+)-channel openers may have a relevant place in the pharmacological treatment of patients with ischemic heart disease.
Cattedra di Cardiologia, II Facoltà di Medicina e Chirurgia, Università degli Studi Federico II, Napoli.
M
M
Chiariello
C
C
Duilio
G
G
Ambrosio
D000787:Angina Pectoris / Q000188:drug therapy; D002986:Clinical Trials as Topic; D003327:Coronary Disease / Q000188:drug therapy*; D006801:Humans; D009536:Niacinamide / Q000031:analogs & derivatives* / Q000494:pharmacology / Q000627:therapeutic use; D020108:Nicorandil; D015221:Potassium Channels / Q000187:drug effects*
D015221:Potassium Channels; D009536:Niacinamide; D020108:Nicorandil
Attività antianginosa dei farmaci attivatori dei canali del potassio.